The method was first described preclinically using vatalanib (formerly PTK787/ZK 222584), a specific inhibitor of the VEGF–receptor tyrosine kinases, which showed anti-tumor and anti-angiogenic activity in a murine renal cell carcinoma (RENCA) model. Here, VEGFA is linked to neoplasm.